# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY AND INSTRUMENT CO M BINATIO N TEMPLATE

A. 510(k) Number: k112161   
B. Purpose for Submission: New device   
C. Measurand: Myoglobin   
D. Type of Test: Quantitative fluorometric immunoassay   
E. Applicant: Radiometer Medical ApS   
F. Proprietary and Established Names: AQT90 Flex Myo Test AQT90 FLEX Myo CAL cartridge AQT90 FLEX LQC Multi-CHECK, Levels 1-3 AQT90 FLEX analyzer

# G. Regulatory Information:

<table><tr><td rowspan=1 colspan=1>Device Name</td><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>AQT90 Flex MyoTest</td><td rowspan=1 colspan=1>DDR: Myoglobinimmunological test</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR §866.5680</td><td rowspan=1 colspan=1>Immunology(82)</td></tr><tr><td rowspan=1 colspan=1>AQT90 FLEX MyoCAL cartridge</td><td rowspan=1 colspan=1>JIT: Calibrator.</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR §862.1150</td><td rowspan=1 colspan=1>ClinicalChemistry(75)</td></tr><tr><td rowspan=1 colspan=1>AQT90 FLEX LQCMulti-CHECK,Levels 1-3</td><td rowspan=1 colspan=1>JJY: Quality controlmaterial</td><td rowspan=1 colspan=1>Class I,reserved</td><td rowspan=1 colspan=1>21 CFR §862.1660</td><td rowspan=1 colspan=1>ClinicalChemistry(75)</td></tr><tr><td rowspan=1 colspan=1>AQT90 FLEX</td><td rowspan=1 colspan=1>KHO: Fluorometerfor clinical use.</td><td rowspan=1 colspan=1>Class I</td><td rowspan=1 colspan=1>21 CFR §862.2560</td><td rowspan=1 colspan=1>ClinicalChemistry(75)</td></tr></table>

# H. Intended Use:

1. Intended use(s): See indications for use below.

2. Indication(s) for use:

AQT90 FLEX analyzer is for in vitro diagnostic use. The instrument is an immunoassay instrument based on the quantitative determination of time-resolved fluorescence to estimate the concentrations of clinically relevant markers on whole-blood and plasma specimens to which a relevant anticoagulant has been added. It is intended for use in point-of-care and laboratory settings.

AQT90 FLEX Myo Test is an in vitro diagnostic assay for the quantitative determination of myoglobin in EDTA or lithium-heparin whole blood or plasma specimens on the AQT90 FLEX analyzer in point of care and laboratory settings. It is indicated for use as an aid in the rapid diagnosis of heart disease, e.g. acute myocardial infarction.

AQT90 FLEX Myo CAL cartridge is for in vitro diagnostic use. For calibration adjustment of the Myo Test, as indicated on the cartridge, on the AQT90 FLEX analyzer.

AQT90 FLEX LQC Multi-CHECK, Levels 1-3, is for in vitro diagnostic use. For use with the AQT90 FLEX analyzer as a liquid quality control serum (LQC) to monitor the precision of laboratory testing procedures for the analytes listed on the specification insert.

3. Special conditions for use statement(s): For prescription use and point-of-care use.

4. Special instrument requirements: AQT90 FLEX analyzer.

# I. Device Description:

<table><tr><td>Component Myoglobin Assay</td><td>Description The AQT90 FLEX Myo Test consists of ten Test cartridges (product</td></tr><tr><td>and Calibrator</td><td>name: AQT90 FLEX Myo Test; function: myoglobin assay reagents) and one Calibration cartridge (product name: AQT90 FLEX Myo CAL; function: calibrator). The Test cartridge contains Test cups whereas the Calibration adjustment cartridge contains both test cups and calibration adjustments cups. The components are listed below: Mouse monoclonal anti-myoglobin capture and tracer • antibodies, approximately 500 ng/cup. Bovine serum albumin. Bovine γ-globulin. Mouse IgG as blocker substance for heterophilic antibody interference. Tris-(hydroxymethyl)-aminomethane (TRIS) buffer Sodium azide &lt; 0.1%. Calibrator Only: Dried reagents including native purified myoglobin (approx. 5 ng/cup).</td></tr><tr><td>Control Material</td><td>AQT90 FLEX LQC Multi-CHECK, Levels 1-3 is comprised of three levels of control material (80, 150 and 315 ng/mL) in human serum. Each human donor unit used to manufacture this control was tested using FDA-accepted methods and found nonreactive for Hepatitis B Surface Antigen (HBsAg), antibody to Hepatitis C (HCV) and antibody to HIV-1/HIV-2.</td></tr><tr><td>Analyzer</td><td>The AQT90 FLEX Analyzer is a cartridge-based immunoassay analyzer which requires the appropriate assay cartridge, the sample and assay buffer. The analyzer has a built-in system to determine the hematocrit value of the whole blood sample aspirated at the start of a test. This value is required to calculate an accurate analyte concentration in plasma. The hematocrit value is determined through a conductivity measurement at two frequencies. The reagent buffer (AQT90 FLEX Reagent Pack) for the analyzer can be purchased separately and is composed of two assay buffer pouches and a waste compartment packed in a cassette. The components of the buffer solution (pH 7.5) for are listed below: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) • Sodium chloride Diazolidinylurea (Germal I I , bactericide), 1 g/L Propyl p-</td></tr></table>

# J. Substantial Equivalence Information:

<table><tr><td rowspan=1 colspan=1>Predicate device name</td><td rowspan=1 colspan=1>Predicate 510(k) number</td></tr><tr><td rowspan=1 colspan=1>Fisher Diagnostics ARCHITECT Stat MyoImmunoassay</td><td rowspan=1 colspan=1>k042924</td></tr><tr><td rowspan=1 colspan=1>Fisher Diagnostics ARCHITECT STAT MyoglobinCalibrators A-F</td><td rowspan=1 colspan=1>k042924</td></tr><tr><td rowspan=1 colspan=1>Bio-Rad Laboratories Liquichek Cardiac Markers PlusControl LT</td><td rowspan=1 colspan=1>k050537</td></tr><tr><td rowspan=1 colspan=1>Abbott Architect iSystem</td><td rowspan=1 colspan=1>k042924</td></tr></table>

Comparison with predicate:   

<table><tr><td colspan="3" rowspan="1">Myoglobin Assay</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Proposed DeviceAQT90 FLEX Myo Test</td><td colspan="1" rowspan="1">Predicate DeviceARCHITECT Stat MyoImmunoassay (k042924)</td></tr><tr><td colspan="1" rowspan="1">Indication for Use</td><td colspan="1" rowspan="1">AQT90 FLEX Myo Test is anin vitro diagnostic assay forthe quantitative determinationof myoglobin</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Matrix</td><td colspan="1" rowspan="1">Whole blood and plasma</td><td colspan="1" rowspan="1">Serum and plasma</td></tr><tr><td colspan="2" rowspan="1">Principle</td><td colspan="1" rowspan="1">Quantitative time-resolvedfluorimetric one-stepsandwich immunoassay</td><td colspan="1" rowspan="1">Quantitative chemiluminescenttwo-step sandwich immunoassay</td></tr><tr><td colspan="2" rowspan="1">Reportable Range</td><td colspan="1" rowspan="1">20 to 900 ng/mL</td><td colspan="1" rowspan="1">0 to 1,200 ng/mL</td></tr><tr><td colspan="2" rowspan="1">Analyzer</td><td colspan="1" rowspan="1">AQT90 FLEX</td><td colspan="1" rowspan="1">ARCHITECT i System</td></tr><tr><td colspan="3" rowspan="1">Analyzer</td><td colspan="1" rowspan="1">EY</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="2" rowspan="1">Proposed DeviceAQT90 FLEX</td><td colspan="1" rowspan="1">Predicate DeviceAbbott Architect iSystem(k042924)</td></tr><tr><td colspan="1" rowspan="1">Indication for Use</td><td colspan="2" rowspan="1">An immunoassay instrumentbased on the quantitativedetermination of time-resolvedfluorescence to estimate theconcentrations of clinicallyrelevant markers on whole-bloodand plasma specimens to whicha relevant anticoagulant has beenadded. It is intended for use inpoint-of-care and laboratorysettings.</td><td colspan="1" rowspan="1">An immunoassay instrumentbased on the quantitativedetermination ofchemiluminescense to measureand quantify analyteconcentration in plasma andserum.</td></tr><tr><td colspan="1" rowspan="1">Test Format</td><td colspan="2" rowspan="1">A completely closed, fullyautomated system, usingcartridge-based immunoassays indisposable cups. Offerspossibility of running 15different parameters at a timeand has a total capacity of 200tests without replenishment.</td><td colspan="1" rowspan="1">The ARCHITECT i System is anopen, fully-automated,immunoassay system allowingrandom and continuous access,and priority processing.</td></tr><tr><td colspan="1" rowspan="1">SpecimenIdentification</td><td colspan="2" rowspan="1">Samples are identified from thebarcode on blood collection testtube. The code is readautomatically by the analyzer.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Specimen Samplingand Handling</td><td colspan="2" rowspan="1">Blood is drawn into normalvacuum test tubes. The bloodcollection tube is placed directlyin the analyzer. A volume ofsample is automatically drawnfrom the tube through its rubberseal. The still closed tube isdiscarded. The usedimmunoassay cup is discardedinto a closed waste bin in theanalyzer.</td><td colspan="1" rowspan="1">Blood is drawn into normalvacuum test tubes, which arecentrifuged to obtain plasma.The blood collection tube isplaced directly in the analyzer. Avolume of sample isautomatically drawn from thetube through its rubber seal. Thestill closed tube is discarded.</td></tr><tr><td colspan="1" rowspan="1">Calibration</td><td colspan="2" rowspan="1">The analyzer can beautomatically calibrated by</td><td colspan="1" rowspan="1">Calibration must be carried outeach time a new reagent lot</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">means of calibration cartridges atthe time of test cartridge lotchange.</td><td colspan="1" rowspan="1">number is used. Calibration isrun automatically.</td></tr><tr><td colspan="1" rowspan="1">Quality Control</td><td colspan="1" rowspan="1">AQT FLEX LQC Multi-CHECK, Levels 1, 2 and 3.</td><td colspan="1" rowspan="1">Architect STAT Controls, Levels1, 2 and 3.</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Calibrator</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Proposed DeviceAQT90 FLEX Myo CALCartridge</td><td rowspan=1 colspan=1>Predicate DeviceARCHITECT STAT MyoglobinCalibrators A-F(k042924)</td></tr><tr><td rowspan=1 colspan=1>Indication forUse</td><td rowspan=1 colspan=1>For calibration adjustment of theMyo Test.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Constituents</td><td rowspan=1 colspan=1>Sixteen calibration adjustmentcups, which contain dried reagentsincluding native purifiedmyoglobin.</td><td rowspan=1 colspan=1>Purified cardiac myoglobin in Trisbuffer with stabilizers</td></tr><tr><td rowspan=1 colspan=1>Traceability</td><td rowspan=1 colspan=1>The calibration is traceable toScripps M0725</td><td rowspan=1 colspan=1>Purified human cardiac myoglobinreference material (primaryreference) is a purchased productwhich is prepared by taking humanheart tissue and mixing it in abuffer solution. The primarycalibrator is then run on acommercially available assay todetermine its concentration.</td></tr><tr><td rowspan=1 colspan=1>Calibrationadjustmentinterval</td><td rowspan=1 colspan=1>Once per lot of AQT90 FLEXMyo Test cartridges and as oftenas required.</td><td rowspan=1 colspan=1>Upon new assay reagent lotnumber</td></tr><tr><td rowspan=1 colspan=1>In-use stability</td><td rowspan=1 colspan=1>24 hours on-board</td><td rowspan=1 colspan=1>30 days at 2-8 °C</td></tr><tr><td rowspan=1 colspan=1>Storagetemperature</td><td rowspan=1 colspan=1>2-8 °</td><td rowspan=1 colspan=1>-10 °</td></tr></table>

<table><tr><td colspan="3" rowspan="1">Control</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Proposed DeviceAQT90 FLEX LQC Multi-CHECK, Levels 1-3</td><td colspan="1" rowspan="1">Predicate DeviceLiquichek Cardiac Markers PlusControl LT (k050537)</td></tr><tr><td colspan="1" rowspan="1">Indication forUse</td><td colspan="1" rowspan="1">For use with the AQT90 FLEXanalyzer as a liquid quality controlserum (LQC) to monitor theprecision of laboratory testingprocedures for the analytes listed</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">on the specification insert.</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Form</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Liquid</td></tr><tr><td colspan="1" rowspan="1">Matrix</td><td colspan="1" rowspan="1">SameEach human donor unit used tomanufacture this control wastested using FDA-acceptedmethods and found nonreactive forHepatitis B Surface Antigen(HBsAg), antibody to Hepatitis C(HCV) and antibody to HIV-1/HIV-2.</td><td colspan="1" rowspan="1">Human serum based</td></tr><tr><td colspan="1" rowspan="1">Traceability</td><td colspan="1" rowspan="1">Scripps M0725</td><td colspan="1" rowspan="1">N/A</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI EP05-A2: Evaluation of Precision Performance of Quantitative Measurement Methods   
CLSI EP6-A: Evaluation of die Linearity of Quantitative Measurement Procedures   
CLSI EP07-A2: Interference Testing in Clinical Chemistry   
CLSI EP09-A2: Method Comparison and Bias Estimation Using Patient Samples   
CLSI EP17-A: Protocols for Determination of Limits of Detection and Limits of   
Quantitation   
CLSI C2S-A3: Defining, Establishing, and Verifying Reference Intervals in die   
Clinical Laboratory   
CLSI I/LA30-A: Immunoassay Interference by Endogenous Antibodies   
EN 13640: Stability Testing of In Vitro Diagnostic Reagents   
ISO 14971: Medical Devices - Application of risk management to medical devices   
ISO 15223-1: Medical Devices - Symbols to be used with medical device labels, labeling and   
information to be supplied

# L. Test Principle:

The test format for the AQT90 FLEX is an immunoassay based on time-resolved fluorescence using an europium (Eu) chelate as the fluorescent label. The test receptacles $( 3 0 0 ~ \mu \mathrm { L }$ test cups) for each assay contain the biotinylated antibodies used for the capture of the analyte, a separating layer of glucosides, and the europium-chelate labeled antibodies used to trace the captured proteins. The sample or diluted sample is added to the test cup together with assay buffer. The cup is then incubated to allow formation of the immunocomplex and washed to remove unbound antibodies and sample materials. Finally, the cup is exposed to excitation light and after a delay, the emitted light is measured by single photon counting; this measurement cycle is repeated up to 3,300 times. The total count (the response) is then compared to a calibration curve to obtain a quantitative measurement of the analyte's concentration in the sample.

# M. Performance Characteristics (if/when applicable):

# 1. Analytical performance:

# a. Precision/Reproducibility:

The precision of the AQT90 Flex Myo Test on the AQT90 FLEX analyzer was evaluated using whole blood and plasma samples at three point of care settings (POC) based upon the CLSI EP5-A2 guideline. Fresh native or antigen spiked lithiumheparin whole blood samples were tested in five replicates in five separate runs within three hours at three POC sites (one instrument, one test kit lot per site). Five levels of frozen native or antigen spiked lithium-heparin plasma were tested in duplicate in two separate runs for twenty days at three POC sites (one instrument, three test kit lots per site). The results are summarized in the following tables.

Summary of Whole Blood Precision Study Results   

<table><tr><td rowspan=2 colspan=1>Site</td><td rowspan=2 colspan=1>Mean(ng/mL)</td><td rowspan=2 colspan=1>N</td><td rowspan=1 colspan=2>Within Run Precision</td><td rowspan=1 colspan=2>Total Precision</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=5 colspan=1>1</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>3.6</td></tr><tr><td rowspan=1 colspan=1>107</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>3.7</td></tr><tr><td rowspan=1 colspan=1>175</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>5.8</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>3.4</td></tr><tr><td rowspan=1 colspan=1>293</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>8.1</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>8.1</td><td rowspan=1 colspan=1>2.8</td></tr><tr><td rowspan=1 colspan=1>585</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>18.0</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>17.9</td><td rowspan=1 colspan=1>3.1</td></tr><tr><td rowspan=5 colspan=1>2</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>2.6</td></tr><tr><td rowspan=1 colspan=1>99</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>3.1</td></tr><tr><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>2.0</td></tr><tr><td rowspan=1 colspan=1>303</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>7.0</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>7.0</td><td rowspan=1 colspan=1>2.3</td></tr><tr><td rowspan=1 colspan=1>572</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>13.3</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>13.3</td><td rowspan=1 colspan=1>2.3</td></tr><tr><td rowspan=5 colspan=1>3</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>2.2</td></tr><tr><td rowspan=1 colspan=1>132</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>2.3</td></tr><tr><td rowspan=1 colspan=1>155</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>3.0</td></tr><tr><td rowspan=1 colspan=1>298</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>6.1</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>7.4</td><td rowspan=1 colspan=1>2.5</td></tr><tr><td rowspan=1 colspan=1>587</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>15.3</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>15.3</td><td rowspan=1 colspan=1>2.6</td></tr></table>

Summary of Plasma Precision Study Results   

<table><tr><td colspan="1" rowspan="2">Site</td><td colspan="1" rowspan="2">Mean(ng/mL)</td><td colspan="1" rowspan="2">N</td><td colspan="2" rowspan="1">Within Run Precision</td><td colspan="2" rowspan="1">Total Precision</td></tr><tr><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td></tr><tr><td colspan="1" rowspan="5">1</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">2.3</td><td colspan="1" rowspan="1">1.9</td><td colspan="1" rowspan="1">4.4</td></tr><tr><td colspan="1" rowspan="1">95</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">1.7</td><td colspan="1" rowspan="1">1.8</td><td colspan="1" rowspan="1">4.0</td><td colspan="1" rowspan="1">4.2</td></tr><tr><td colspan="1" rowspan="1">198</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">4.3</td><td colspan="1" rowspan="1">2.2</td><td colspan="1" rowspan="1">6.3</td><td colspan="1" rowspan="1">3.2</td></tr><tr><td colspan="1" rowspan="1">378</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">7.9</td><td colspan="1" rowspan="1">2.1</td><td colspan="1" rowspan="1">12.0</td><td colspan="1" rowspan="1">3.2</td></tr><tr><td colspan="1" rowspan="1">706</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">19.0</td><td colspan="1" rowspan="1">2.7</td><td colspan="1" rowspan="1">29.5</td><td colspan="1" rowspan="1">4.2</td></tr><tr><td colspan="1" rowspan="5">2</td><td colspan="1" rowspan="1">43</td><td colspan="1" rowspan="1">82</td><td colspan="1" rowspan="1">0.6</td><td colspan="1" rowspan="1">1.5</td><td colspan="1" rowspan="1">2.2</td><td colspan="1" rowspan="1">5.2</td></tr><tr><td colspan="1" rowspan="1">98</td><td colspan="1" rowspan="1">84</td><td colspan="1" rowspan="1">2.1</td><td colspan="1" rowspan="1">2.1</td><td colspan="1" rowspan="1">5.0</td><td colspan="1" rowspan="1">5.1</td></tr><tr><td colspan="1" rowspan="1">205</td><td colspan="1" rowspan="1">84</td><td colspan="1" rowspan="1">3.9</td><td colspan="1" rowspan="1">1.9</td><td colspan="1" rowspan="1">8.5</td><td colspan="1" rowspan="1">4.1</td></tr><tr><td colspan="1" rowspan="1">389</td><td colspan="1" rowspan="1">84</td><td colspan="1" rowspan="1">13.5</td><td colspan="1" rowspan="1">3.5</td><td colspan="1" rowspan="1">18.3</td><td colspan="1" rowspan="1">4.7</td></tr><tr><td colspan="1" rowspan="1">722</td><td colspan="1" rowspan="1">84</td><td colspan="1" rowspan="1">16.9</td><td colspan="1" rowspan="1">2.3</td><td colspan="1" rowspan="1">36.8</td><td colspan="1" rowspan="1">5.1</td></tr><tr><td colspan="1" rowspan="3">3</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">0.9</td><td colspan="1" rowspan="1">2.1</td><td colspan="1" rowspan="1">2.0</td><td colspan="1" rowspan="1">4.6</td></tr><tr><td colspan="1" rowspan="1">99</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">2.5</td><td colspan="1" rowspan="1">2.5</td><td colspan="1" rowspan="1">5.3</td><td colspan="1" rowspan="1">5.3</td></tr><tr><td colspan="1" rowspan="1">205</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">4.4</td><td colspan="1" rowspan="1">2.1</td><td colspan="1" rowspan="1">8.9</td><td colspan="1" rowspan="1">4.3</td></tr><tr><td colspan="1" rowspan="1">389</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">6.6</td><td colspan="1" rowspan="1">1.7</td><td colspan="1" rowspan="1">16.1</td><td colspan="1" rowspan="1">4.1</td></tr><tr><td colspan="1" rowspan="1">727</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">17.4</td><td colspan="1" rowspan="1">2.4</td><td colspan="1" rowspan="1">35.0</td><td colspan="1" rowspan="1">4.8</td></tr></table>

$b$ . Linearity/assay reportable range:

The linearity of the AQT90 FLEX Myo Test was evaluated on the AQT90 FLEX analyzer by diluting two spiked plasma and whole blood samples with various levels of diluent to obtain twelve levels for each matrix. The plasma samples had values ranging from 0.04 to $1 1 0 8 ~ \mathrm { { n g / m L } }$ while the blood samples ranged from 0.14 to 1766 $\mathrm { n g / m L }$ . The linear regression correlation is $\mathrm { y } = 0 . 9 8 \mathrm { x } - 4 . 2 1$ for plasma samples and $\mathrm { y } = 1 . 0 0 + 0 . 3 6$ for whole blood samples. The data provided support the sponsor’s claims that the reportable range of this assay is 20 to $9 0 0 ~ \mathrm { { n g / m L } }$ .

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

# Traceability and Value Assignment

The antigen material, M0725 by Scripps, has been used to establish the metrological traceability chain of the AQT90 FLEX Myo assay because there is no international conventional calibrator for myoglobin. The nominal concentration of the reference material at each concentration level has been defined by weighing the fraction of the reference material and the buffer solution.

This material has been used to assign values for the manufacturer's working calibrator with the manufacturer's selected measurement procedure. In summary, the reference material (eight concentration points) and the calibrator material (eight concentration points) have been measured with two instruments, two reagent batches, over three days and with four replicate measurements. Altogether this yields a total of 48 individual results produced by a known amount of specific protein from all reference and calibrator points.

The success of the value assignment and commutability of the two materials have been estimated by measuring patient samples against the standard curves of these two materials. The regression of averages of these concentrations was evaluated. The slope was not statistically significantly different from the expected value of 1, and the calculated intercept was not statistically different from the expected value of 0. This confirms the commutability of the materials.

The traceability chain from the manufacturer's working calibrator to the product calibrator is performed for all AQT90 FLEX Myo batches using three instruments, two runs and five replicate measurements. The value assignment from the working calibrator to the product calibrator and generation of the factory standard curve are done with total of 30 individual results of the manufacturer's working calibrator.

Control material was purchased from commercial available sources. The value assignment for each Multi-CHECK level includes two AQT90 FLEX Myo Test reagent lots, three AQT90 FLEX analyzers, two test days and five measurement replicates per control level for a total of 60 measurements per control level.

# Stability

AQT90 FLEX Myo Test and Calibration Cartridges: The shelf life stability studies were performed on three product lots of test and calibration cartridges. The product was kept at $2 - 8 ~ ^ { \circ } \mathrm { C }$ and tested at different time points during ten months on the AQT90 FLEX analyzer. On-board stability was studied with three product lots of test and calibration cartridges stored at $2 - 8 ~ ^ { \circ } \mathrm { C }$ , placed at $3 2 ^ { \circ } \mathrm { C }$ and tested at indicated time points (zero, six and eight months) on the AQT90 FLEX analyzer. Based on the results, the sponsor claims that test and calibration cartridges are claimed to have a shelf stability of 8 months at 2 to $\underline { { 8 \ : ^ { \circ } \mathrm { C } } } ,$ while the on-board stability is 16 days at $3 2 ~ \mathrm { { ^ \circ C } }$ for the test cartridge and 48 hours at $3 2 ~ \mathrm { { ^ \circ C } }$ for the calibration cartridge.

AQT90 FLEX LQC Multi-Check: Shelf life stability studies were performed on three lots. The product was kept at -18 to ${ } _ { - 2 6 } { } ^ { \circ } \mathrm { C }$ , placed at 2 to $8 ~ ^ { \circ } \mathrm { C }$ and tested at different time points up to fifteen months on the AQT90 FLEX analyzer. On-board stability was studied with three product lots placed at either $8 ~ ^ { \circ } \mathrm { C }$ or $3 2 ~ \mathrm { { ^ { o } C } }$ and tested at different time points up to fifteen hours on the AQT90 FLEX analyzer. Based on the results, the sponsor claims a shelf stability of 12 months at $\underline { { - 1 8 } }$ to ${ \underline { { - 2 6 } } } ^ { \circ } \mathrm { C } ,$ while the on-board stability is 4 days unopened at 2 to $8 ~ ^ { \circ } C$ or 2 hours opened at room temperature.

AQT90 FLEX Reagent Pack: Shelf life stability studies were performed on three product lots. The product was kept at $3 2 ~ ^ { \circ } \mathrm { C }$ and tested at different time points up to fifteen months on the AQT90 FLEX analyzer. On-board stability was studied with one product lot placed at 32 to $4 0 ~ ^ { \circ } \mathrm { C }$ and tested at different time points on the AQT90 FLEX analyzer. Based on the results, the sponsor claims a shelf stability of 5 months at 2 to $3 2 ^ { \circ } \mathrm { C } .$ , while the on-board stability is 25 days at room temperature.

# d. Detection limit:

The Limit of Blank (LoB) determination was based on 64 replicate measurements of AQT Assay Buffer on a single AQT90 FLEX instrument according to CLSI EP 17-A. The Limit of Blank as determined by the upper $9 5 ^ { \mathrm { t h } }$ percentile is $0 . 0 3 7 ~ \mathrm { n g / m L }$ . The Limit of Blank claim in the package insert is $0 . 5 ~ \mathrm { { n g / m L } }$ .

Limit of Detection (LoD) determination was based on 20 replicate measurements of four low samples on an AQT90 FLEX instrument. The LoD determination was calculated by using the determined LoB value and pooled SD values from LoD samples. The Limit of Detection was determined to be $0 . 2 ~ \mathrm { n g / m L }$ for BSA-buffer supplemented with red blood cells. The Limit of Detection claim in the package insert is $1 . 0 \ : \mathrm { n g / m L }$ .

Limit of Quantitation (LoQ) determination was based on 30 replicate measurements of four low samples on two AQT90 FLEX instruments. The Limit of Quantitation was determined to be $0 . 6 ~ \mathrm { { n g / m L } }$ for BSA-buffer supplemented with red blood cells. The Limit of Quantitation claim in the package insert is $1 . 0 \ : \mathrm { n g / m L }$ .

The AQT90 FLEX Myo Test has a reportable range of $2 0 { - } 9 0 0 ~ \mathrm { n g / m L }$

e. Analytical specificity:

Interference studies were designed according to the CLSI EP7-A guideline. Two levels of human plasma (100 and $5 0 0 ~ \mathrm { { n g / m L } }$ ) were spiked with known interference substances (51 drugs, 3 solvents and 13 endogenous compounds) and samples were analyzed in five replicates on the AQT90 FLEX analyzer. No significant interference, defined as recovery within $\pm 1 0 \%$ compared to reference without any interfering substance, was observed with the assay. Specifically, no interference was observed with unconjugated Bilirubin up to $2 7 0 \mathrm { m g / L }$ $( 2 7 . 0 \mathrm { m g / d L } )$ ), conjugated Bilirubin up to $2 7 0 ~ \mathrm { { m g / L } }$ $( 2 7 . 0 \mathrm { m g / d L } )$ , Hemoglobin up to $1 0 ~ \mathrm { g / L }$ ( $1 0 0 0 \mathrm { m g / d L } )$ and triglycerides up to $1 5 \ \mathrm { g / L }$ ( $1 5 0 0 \mathrm { m g / d L } )$ .

The potential interference of thirteen endogenous compounds was evaluated in whole blood samples. Similar to the results observed with plasma samples, no interference was observed with unconjugated Bilirubin up to $2 7 0 ~ \mathrm { { m g / L } }$ $( 2 7 . 0 \mathrm { m g / d L } )$ ),conjugated Bilirubin up to $2 7 0 ~ \mathrm { { m g / L } }$ $( 2 7 . 0 \ : \mathrm { m g / d L } )$ , Hemoglobin up to $1 0 \ \mathrm { g / L }$ ( $1 0 0 0 \mathrm { m g / d L } )$ , and triglycerides up to $1 5 \ \mathrm { g / L }$ ( $1 5 0 0 \mathrm { m g / d L } )$ .

No hook effect was observed for plasma samples up to $1 { , } 9 5 0 \mathrm { n g / m L }$ and up to 6,500 $\mathrm { n g / m L }$ with whole blood samples, which are outside of the reportable range of 20 to $9 0 0 ~ \mathrm { { n g / m L } }$ .

Potential positive interference from human anti-mouse antibody (HAMA) and Rheumatoid factor (RF) was evaluated (five replicate measurements) using seventeen human plasma samples containing HAMA and/or RF. The sponsor claims no positive interference from human anti-mouse antibody (HAMA) and Rheumatoid factor (RF).

Possible negative interference from HAMA and RF was evaluated by comparing the results of seventeen human HAMA and/or RF plasma samples spiked with myoglobin to reference sample (HAMA/RF negative) containing the same amount of myoglobin. No negative interference for the assay was observed, which was defined as recovery within $\pm 1 0 \%$ of human HAMA/RF positive samples compared to a reference sample (HAMA/RF negative). The sponsor claims no negative interference from human antimouse antibody (HAMA) and Rheumatoid factor (RF).

f. Assay cut-off: Not applicable

2. Comparison studies:

a. Method comparison with predicate device:

Paired human whole blood and lithium-heparin plasma samples were collected at four hospitals and measurements were obtained using the AQT90 FLEX Myo Test run on the AQT90 FLEX analyzer. Frozen plasma samples were sent to a central laboratory and comparative measurements were obtained on the predicate device (ARCHITECT STAT Myoglobin Immunoassay on the ARCHITECT I System). For lithium plasma, 165 samples (including nine spiked samples) were evaluated and the total range of

samples tested was 22 to $8 8 2 ~ \mathrm { n g / m l }$ . For whole blood, 157 samples (no spiked samples), with a sample range of 24 to $8 5 6 ~ \mathrm { { n g / m l } }$ , were evaluated. The data was evaluated by the Passing-Bablok linear regression analysis and the results were as follows.

Plasma samples: $\begin{array} { r } { \mathbf { y } = 1 . 0 2 \mathbf { x } + 1 3 , \mathbf { r } ^ { 2 } = 0 . 9 9 , \mathbf { n } = 1 6 5 \mathbf { \Omega } } \\ { \mathbf { y } = 1 . 0 7 \mathbf { x } + 1 5 , \mathbf { r } ^ { 2 } = 0 . 9 9 , \mathbf { n } = 1 5 7 \mathbf { \Omega } } \end{array}$ Whole blood samples:

b. Matrix comparison:

In order to demonstrate equivalence of myoglobin results between different anticoagulant combinations, sixty four individual and five spiked samples spanning the measuring range (24 to $8 8 9 ~ \mathrm { n g / m L }$ ) were evaluated. Four matrix anticoagulant combinations were evaluated in the study, which were Lithium-Heparin whole blood, Lithium-Heparin plasma, EDTA whole blood and EDTA plasma. The results of plasma versus whole blood were analyzed by Passing-Bablock regression. Results are summarized below:

Li-Hep Plasma vs. Li-Hep WB: $\mathbf { y } = 0 . 9 9 \mathbf { x } - 1 . 0 ,$ , $\mathrm { r } ^ { 2 } = 1 . 0 0$ , ${ \mathfrak { n } } = 6 9$ EDTA Plasma vs. EDTA WB: $\mathbf { y } = 1 . 0 0 \mathbf { x } - 0 . 5 , \mathbf { r } ^ { 2 } = 1 . 0 0 , $ ${ \mathfrak { n } } = 6 9$ EDTA WB vs. Li-Hep Plasma: $\mathbf { y } = 1 . 0 2 \mathbf { x } - 0 . 9 , \mathbf { r } ^ { 2 } = 1 . 0 0 , \mathbf { n } = 6 4$ EDTA Plasma vs. Li-Hep Plasma: $\mathbf { y } = 1 . 0 1 \mathbf { x } + 0 . 3$ , $\mathrm { r } ^ { 2 } = 1 . 0 0$ , ${ \mathfrak { n } } = 6 4$

Abbreviations Used: Lithium-Heparin $=$ Li-Hep and Whole Blood $=$ WB

3. Clinical studies:

a. Clinical Sensitivity: Not applicable   
b. Clinical specificity: Not applicable   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: The $9 7 . 5 ^ { \mathrm { t h } }$ Percentile was determined for women ( $7 5 ~ \mathrm { n g / m L }$ ) and men $\mathrm { 1 4 2 \ n g / m L ) }$ .

5. Expected values/Reference range:

Whole blood (lithium-heparin and EDTA) and plasma (lithium-heparin and EDTA) were obtained from 343 apparently healthy individuals (ages: 21 to 86 years) from a geographically diverse U.S. adult population (182 women and $1 6 1 \mathrm { \ m e n } ,$ ) and analyzed using the AQT90 FLEX Myo assay. The data is summarized in the following table.

<table><tr><td colspan="1" rowspan="1">Category</td><td colspan="1" rowspan="1">95% ReferenceInterval (ng/mL)</td><td colspan="1" rowspan="1">97.5th Percentile(ng/mL)</td><td colspan="1" rowspan="1">90% ConfidenceInterval for 97.5thPercentile (ng/mL)</td></tr><tr><td colspan="1" rowspan="1">Women</td><td colspan="1" rowspan="1">20 to 75</td><td colspan="1" rowspan="1">75</td><td colspan="1" rowspan="1">69 to 82</td></tr><tr><td>Men</td><td>24 to 142</td><td>142</td><td>124 to 164</td></tr><tr><td></td><td></td><td></td><td></td></tr></table>

Each laboratory should establish its own reference range.

# N. Instrument Name:

AQT90 FLEX analyzer

# O. System Descriptions:

1. Modes of Operation:

A completely closed, fully automated system, using cartridge-based immunoassays in disposable cups. Offers possibility of running 15 different parameters at a time and has a total capacity of 200 tests without replenishment.

2. Software:

FDA has reviewed applicant’s Hazard Analysis and software development processes for this line of product types:

Yes ___X____ or No _

3. Specimen Identification:

Samples are identified from the barcode on blood collection test tube. The code is read automatically by the analyzer.

4. Specimen Sampling and Handling:

Blood is drawn into normal vacuum test tube. The blood collection tube is placed directly in the analyzer. A volume of sample is automatically drawn from the tube through its rubber seal. The still closed tube is discarded. The used immunoassay cup is discarded into a closed waste bin in the analyzer.

5. Calibration:

The analyzer can be automatically calibrated by means of calibration cartridges at the time of test cartridge lot change.

6. Quality Control: AQT FLEX LQC Multi-CHECK, Levels 1, 2 and 3.

# P. O therSupportiveInstrum entPerform anceCharacteristicsDataNotCovered In The “Performance Characteristics” Section above:

The sponsor conducted testing on plasma and whole blood samples to estimate the carry-over of myoglobin between samples analyzed on the AQT90 FLEX Analyzer. The detected maximum carry-over was 203 ppm for plasma and $2 5 3 \mathrm { p p m }$ for whole blood.

# Q. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# R. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.